Ask what symptoms should be evaluated first, whether labs or stool testing are appropriate, what the research actually supports, what is still unknown, how safety would be monitored, and how progress would be measured
Marketing Policy Option 13: HHS could allow joint state/CMS review of marketing materials and explore opportunities for states to review materials via the CMS HPMS
doi: 10.1111/obr.12436
Patients with partial or complete DPD deficiency are at high risk for severe, sometimes fatal toxicity when treated with fluoropyrimidines such as capecitabine
The platform provides access to physician guidance, follow-up support, and treatment management through the Medvi patient portal
KLOW at a Glance Who Benefits Most from KLOW In my experience, KLOW is the right call for three distinct groups: The autoimmune / histamine-prone: those with high food intolerances, MCAS, or autoimmune conditions who experience high systemic inflammation